BridgeBio Pharma BBIO Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $579.96M+355% | $502.08M+126% | $353.78M+62.5% | $235.81M+7.6% | $127.42M-41.7% | ||
| $28.26M+377% | $20.96M+441% | $14.94M+525% | $8.97M+275% | $5.92M+147% | ||
| $551.7M+354% | $481.11M+121% | $338.84M+57.3% | $226.84M+4.7% | $121.5M-43.8% | ||
| 95.1%-0.2pp | 95.8%-2.4pp | 95.8%-3.1pp | 96.2%-2.7pp | 95.4%-3.6pp | ||
| $467.16M-2.0% | $451.95M-10.8% | $465.89M-8.0% | $473.46M-7.4% | $476.92M-5.3% | ||
| $588.76M+78.7% | $531.23M+83.9% | $467.92M+93.6% | $399.12M+91.3% | $329.49M+77.8% | ||
| $1.1B+33.9% | $1.03B+25.8% | $963.66M+26.4% | $892.24M+22.3% | $825.1M+18.0% | ||
| -$525M+24.8% | -$523.41M+11.7% | -$609.88M-12.0% | -$656.43M-28.6% | -$697.69M-45.1% | ||
| -90.5%+457pp | -104.2%+163pp | -172.4%+77.6pp | -278.4%-45.5pp | -547.6%-328pp | ||
| $73.95M-13.6% | $79.13M-13.0% | $89.02M-0.8% | $100.34M+15.4% | $85.64M+1.2% | ||
| $20.72M+11.6% | $19.85M+15.1% | $20.21M+11.4% | $17.26M-7.4% | $18.56M+3.3% | ||
| -$204.46M— | -$209.09M— | —— | —— | —— | ||
| -$75.34M-61.2% | -$72.61M-133% | -$68.27M-371% | -$59M-645% | -$46.74M— | ||
| $0+100% | -$21.16M+20.4% | -$21.16M+20.4% | -$21.16M+20.4% | -$21.16M+20.4% | ||
| -$729.89M-7.8% | -$732.94M-34.9% | -$805.69M-80.5% | -$785.01M-70.1% | -$676.8M-23.8% | ||
| -125.9%+405pp | -146%+98.9pp | -227.7%-22.8pp | -332.9%-122pp | -531.2%-281pp | ||
| -$3.73-5.1% | -$3.77-31.4% | -$4.20-74.3% | -$4.11-56.3% | -$3.55-10.2% | ||
| -$3.73-5.1% | -$3.77-31.4% | -$4.20-74.3% | -$4.11-56.3% | -$3.55-10.2% | ||
| 768.7M+2.2% | 764M+3.1% | 758.6M+5.7% | 755.2M+9.1% | 752.3M+13.1% | ||
| 768.7M+2.2% | 764M+3.1% | 758.6M+5.7% | 755.2M+9.1% | 752.3M+13.1% | ||
| $140.99M— | $125.14M— | $94.76M— | $58.35M— | —— | ||
| $39.08M+255% | $43.06M+251% | $32.86M+1.4% | $18.2M-28.2% | $11.02M-59.9% | ||
| $20.78M+62.6% | $21.35M+36.8% | $14.91M+15.6% | $10.69M+4.2% | $12.78M+36.7% | ||
| $579.96M+355% | $502.08M+126% | $353.78M+62.5% | $235.81M+7.6% | $127.42M-41.7% | ||
| -$525M+24.8% | -$523.41M+11.7% | -$609.88M-12.0% | -$656.43M-28.6% | -$697.69M-45.1% | ||
| -$519.66M+24.9% | -$517.98M+11.7% | -$604.51M-12.3% | -$650.92M-29.2% | -$691.93M-45.9% | ||
| -$519.66M+24.9% | -$517.98M+11.7% | -$604.51M-12.3% | -$650.92M-29.2% | -$691.93M-45.9% | ||
| -89.6%+453pp | -103.2%+161pp | -170.9%+76.2pp | -276%-46.1pp | -543%-326pp | ||
| -$525M+24.8% | -$523.41M+11.7% | -$609.88M-12.0% | -$656.43M-28.6% | -$697.69M-45.1% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is BridgeBio Pharma's revenue?
- BridgeBio Pharma (BBIO) generated $580.0M in revenue over the trailing twelve months, up 355.2% year over year.
- Is BridgeBio Pharma profitable?
- BridgeBio Pharma is not currently profitable: it reported a net loss of $729.9M over the trailing twelve months, a -125.9% net margin.
- What are BridgeBio Pharma's profit margins?
- Gross margin is 95.1% and operating margin is -90.5%, with a -125.9% net margin.
- What is BridgeBio Pharma's earnings per share?
- BridgeBio Pharma's diluted EPS over the trailing twelve months is $-3.73.
- Where does BridgeBio Pharma's income statement data come from?
- Every line is extracted from BridgeBio Pharma's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
